CHCT shorts retreat as EPS momentum builds

CHCT heads into the week following its Q1 earnings release with short sellers pulling back and options traders more bullish than they have been all year — a notable shift for a small healthcare REIT that spent much of March and April under steady selling pressure.

The clearest move is in short positioning. Short interest has fallen roughly 21% over the past month, dropping to 2.7% of the free float from a peak close to 3.4% around early April. The retreat has been consistent rather than episodic — shorts have trimmed every week since mid-April. Cost to borrow is unchanged at around 0.5%, effectively free money to borrow, and borrow availability is exceptionally loose at nearly 1,800% of current short interest. That combination tells a plain story: shorts are leaving because they want to, not because they are being squeezed out.

Options positioning reinforces the bullish read. The put/call ratio has dropped to 0.25, its lowest level of the past 52 weeks and about one standard deviation below its 20-day average of 0.44. That is the most call-heavy options market CHCT has seen in a year. The shift is sharp: the PCR ran in the 0.67–0.69 range through most of April, then broke decisively lower from late April onward. The ORTEX short score, at 34.4, has drifted lower over the past two weeks, corroborating the reduced bearish conviction.

The Street's posture is mixed but tilting cautious-constructive. Truist Securities holds a Buy with a $19 target, having trimmed it from $20 back in early March. Piper Sandler kept Neutral with an $18 target after a small raise in February; Evercore maintained In-Line at $17 after a similar lift. The mean target across coverage implies about 5% upside from the $17.64 close, which is modest but positive against a stock that trades at a significant discount to NAV — the bear case flags the 2026 FFO multiple at 8.3x versus a historical average closer to 13x, pointing to weak investor confidence in growth recovery. The bull case counters with consistent quarterly dividend increases since IPO and a 4.1% projected average annual FFO growth through 2031. Factor scores add nuance: EPS surprise ranks at the 98th percentile, and the 12-month forward EPS growth score is at the 89th percentile — the company has been beating estimates convincingly, even as absolute valuation remains compressed.

The institutional register shows Mirae Asset building a 704,000-share position in the most recent period, the largest single-quarter addition in the top-15 holder list. Vanguard and BlackRock both made modest additions. Kennedy Capital added 213,000 shares through February. These are steady accumulation moves rather than aggressive pivots, consistent with value-oriented buyers picking at a NAV-discount name with a reliable income stream.

The Q1 results arrived this week — the earnings history shows only one prior trading reaction with data (April 28 Q4 print: -0.7% on the day, +1.5% over five days), too thin to draw a pattern. What is worth watching next is whether the short-interest retreat holds now that results are out, and whether the call-heavy options positioning resolves into price gains or simply fades as near-term catalysts pass. With peers ARE and DHC both rising 6–8% on the week, sector tailwinds appear supportive — but CHCT's relative underperformance on the week (+0.3% versus that peer strength) suggests the stock remains in a catch-up trade rather than a momentum one.